References

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

10.1016/j.annonc.2022.05.520 · 2022 · External reference

Liquid biopsy for advanced NSCLC: A consensus statement from the International Association for the Study of Lung Cancer

10.1016/j.jtho.2021.06.017 · 2021 · External reference

Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer

10.1056/nejmoa2202170 · 2022 · External reference

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

10.1016/s1470-2045(22)00518-6 · 2022 · External reference

Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non–small cell lung cancer (IMpower010): An open-label, randomized, phase III trial

10.1200/jco-24-01681 · 2025 · External reference

Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer: Updated results from the phase III randomized ADAURA trial

10.1200/jco.22.02186 · 2023 · External reference

Alectinib in resected ALK -positive non–small-cell lung cancer

10.1056/nejmoa2310532 · 2024 · External reference

Selpercatinib in early-stage RET fusion–positive non–small-cell lung cancer

10.1056/nejmoa2602628 · 2026 · External reference

Overall survival with osimertinib in resected EGFR -mutated NSCLC

10.1056/nejmoa2304594 · 2023 · External reference

Advancing neoadjuvant therapies in resectable non-small cell lung cancer: Implications for novel treatment strategies and biomarker discovery

10.3389/pore.2024.1611817 · 2024 · External reference

Perioperative durvalumab for resectable non–small-cell lung cancer

10.1056/nejmoa2304875 · 2023 · External reference

Perioperative pembrolizumab for early-stage non–small-cell lung cancer

10.1056/nejmoa2302983 · 2023 · External reference

Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: A narrative review

10.1001/jamaoncol.2022.4457 · 2022 · External reference

Implementing ctDNA analysis in the clinic: Challenges and opportunities in non-small cell lung cancer

10.3390/cancers12113112 · 2020 · External reference

Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting

10.1007/s12672-026-04495-2 · 2026 · External reference

Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: Are we there yet

10.1586/14737159.2015.1110021 · 2015 · External reference

A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer

10.1038/s41698-025-00984-9 · 2025 · External reference

Circulating tumor DNA minimal residual disease detection of non–small-cell lung cancer treated with curative intent

10.1200/jco.21.01929 · 2022 · External reference

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

10.1038/nature22364 · 2017 · External reference

Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study

10.1200/jco.2018.36.15_suppl.12003 · 2018 · External reference

Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer

10.1002/cncr.35263 · 2024 · External reference

1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

10.1016/j.iotech.2022.100106 · 2022 · External reference

Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC)

10.1200/jco.2024.42.16_suppl.8078 · 2024 · External reference

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

10.1038/s41587-021-00981-w · 2021 · External reference

Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring

10.1038/s41591-020-0915-3 · 2020 · External reference

Correction: Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay

10.18632/oncotarget.28581 · 2024 · External reference

Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction

10.1016/j.cell.2025.10.020 · 2025 · External reference

Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)

10.1016/j.annonc.2023.12.007 · 2024 · External reference

Minimal residual disease as a target for liquid biopsy in patients with solid tumours

10.1038/s41571-024-00967-y · 2025 · External reference

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels

10.1016/j.annonc.2023.06.001 · 2023 · External reference

Minimal residual disease monitoring in radically treated non-small cell lung cancer: Challenges and future directions

10.2147/ott.s322242 · 2023 · External reference

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology

10.1038/s41698-025-00876-y · 2025 · External reference

Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: Advances and challenges

10.1002/mco2.766 · 2024 · External reference

Predictive effectiveness of circulating tumor DNA in recurrent early-stage non–small cell lung cancer: An updated meta-analysis

10.1200/po-25-00489 · 2025 · External reference

Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer

10.1016/j.jtho.2026.104090 · 2026 · External reference

Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients

10.1002/1878-0261.13267 · 2022 · External reference

Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling

10.1158/2159-8290.cd-17-0716 · 2017 · External reference

Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC)

10.1158/1078-0432.ccr-19-1213 · 2019 · External reference

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

10.1038/s41586-023-05776-4 · 2023 · External reference

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer

10.1016/j.annonc.2022.02.007 · 2022 · External reference

Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer

10.1158/2159-8290.cd-21-1486 · 2022 · External reference

Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

10.1016/s1470-2045(24)00498-4 · 2024 · External reference

Association between pathologic response and survival after neoadjuvant therapy in lung cancer

10.1038/s41591-023-02660-6 · 2024 · External reference

LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial

10.1016/j.annonc.2023.10.055 · 2023 · External reference

Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial

10.1200/jco.2025.43.16_suppl.8009 · 2025 · External reference

Biomarkers of nivolumab benefit in resectable non-small cell lung cancer

10.1038/s41586-026-10925-6 · 2026 · External reference

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer

10.1038/s41591-025-03577-y · 2025 · External reference

OA02.02 Molecular residual disease (MRD) analysis from NeoADAURA: Neoadjuvant osimertinib ± chemotherapy in resectable EGFRm NSCLC

10.1016/j.jtho.2025.09.032 · 2025 · External reference

1817MO Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC

10.1016/j.annonc.2025.08.2443 · 2025 · External reference

Adjuvant durvalumab in completely resected early-stage non–small cell lung cancer

10.1200/jco-25-01828 · 2026 · External reference

Adjuvant nivolumab vs observation in resected non–small cell lung cancer: A randomized clinical trial

10.1001/jama.2026.8992 · 2026 · External reference

ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

10.1016/j.lungcan.2025.108635 · 2025 · External reference

Circulating mutant DNA to assess tumor dynamics

10.1038/nm.1789 · 2008 · External reference

Unresolved reference

External reference

Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in NSCLC

10.1016/j.jtho.2024.03.010 · 2024 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer

10.1186/s12916-023-02954-z · 2023 · External reference

Unresolved reference

External reference

Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer

10.1056/nejmoa2200075 · 2022 · External reference

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: The randomized phase 2/3 DYNAMIC-III trial

10.1038/s41591-025-04030-w · 2025 · External reference

ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: Results from the TOMBOLA trial

10.1016/j.annonc.2025.12.018 · 2026 · External reference

Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer

10.1038/s43018-019-0011-0 · 2020 · External reference